Skip to content

Study · Non-randomized trial · 2000

8 results

Oral Cerebrolysin enhances brain alpha activity and improves cognitive performance in elderly control subjects.

Alvarez XA, Lombardi VR, Corzo L, Pérez P, Pichel V, Laredo M, Hernández A, Freixeiro F, Sampedro C, Lorenzo R, Alcaraz M, Windisch M, Cacabelos R

Journal of neural transmission. Supplementum1 Jan 2000Cited by 11 (Europe PMC)

PMID10961443 (opens in a new tab)DOI10.1007/978-3-7091-6781-6_33 (opens in a new tab)PepBankPUB-10961443
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In healthy elderly people, oral Cerebrolysin progressively increased relative alpha power after treatment.

    In plain wordsIn healthy elderly people, oral Cerebrolysin increased brain alpha activity compared with baseline.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseRelative alpha activity across electrodes
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    30 ml · oralAs given in this study (human).

    Source sentences

    Summary
    A single oral dose of Cerebrolysin induced a progressive increase in relative alpha activity power from 1 to 6 hours after treatment in almost all the brain electrodes in elderly control subjects.
    1 context sentence
    Summary · context
    The effects of a single oral dose of the Cerebrolysin solution (30 ml) on brain bioelectrical activity and on cognitive performance were investigated in healthy elderly people.
  2. 02HumanNon-randomized trialEfficacy outcome

    In healthy elderly people, Cerebrolysin increased left occipital alpha power at 1 hour compared with baseline.

    In plain wordsIn healthy elderly people, Cerebrolysin increased left occipital alpha activity at 1 hour compared with baseline.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseLeft occipital alpha power at 1 hour
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    30 ml · oralAs given in this study (human).

    Measurements

    Baseline alpha power
    45.8%
    baseline
    Alpha power
    57.2%
    1 hour
    Baseline alpha power uncertainty (unspecified +/-)
    9.5%
    baseline alpha power 45.8%
    Alpha power uncertainty (unspecified +/-)
    8.5%
    1 hour alpha power after Cerebrolysin treatment
    Alpha power comparison p value
    < 0.05 p value
    left occipital electrode O1, 1 hour after Cerebrolysin versus baseline

    Source sentences

    Summary
    As compared with baseline alpha power (45.8+/-9.5%), the increase in relative alpha activity in the left occipital electrode (O1) reached significant values at 1 hour (57.2+/-8.5%; p < 0.05), 3 hours (59.4+/-7.6%; p < 0.05) and 6 hours (63.4+/-9.8%; p < 0.05) after Cerebrolysin administration.
    1 context sentence
    Summary · context
    The effects of a single oral dose of the Cerebrolysin solution (30 ml) on brain bioelectrical activity and on cognitive performance were investigated in healthy elderly people.
  3. 03HumanNon-randomized trialEfficacy outcome

    In healthy elderly people, Cerebrolysin increased left occipital alpha power at 3 hours compared with baseline.

    In plain wordsIn healthy elderly people, Cerebrolysin increased left occipital alpha activity at 3 hours compared with baseline.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseLeft occipital alpha power at 3 hours
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    30 ml · oralAs given in this study (human).

    Measurements

    Baseline alpha power
    45.8%
    baseline
    Alpha power
    59.4%
    3 hours
    Baseline alpha power uncertainty (unspecified +/-)
    9.5%
    baseline alpha power 45.8%
    Alpha power uncertainty (unspecified +/-)
    7.6%
    3 hour alpha power after Cerebrolysin treatment
    Alpha power comparison p value
    < 0.05 p value
    left occipital electrode O1, 3 hour after Cerebrolysin versus baseline

    Source sentences

    Summary
    As compared with baseline alpha power (45.8+/-9.5%), the increase in relative alpha activity in the left occipital electrode (O1) reached significant values at 1 hour (57.2+/-8.5%; p < 0.05), 3 hours (59.4+/-7.6%; p < 0.05) and 6 hours (63.4+/-9.8%; p < 0.05) after Cerebrolysin administration.
    1 context sentence
    Summary · context
    The effects of a single oral dose of the Cerebrolysin solution (30 ml) on brain bioelectrical activity and on cognitive performance were investigated in healthy elderly people.
  4. 04HumanNon-randomized trialEfficacy outcome

    In healthy elderly people, Cerebrolysin increased left occipital alpha power at 6 hours compared with baseline.

    In plain wordsIn healthy elderly people, Cerebrolysin increased left occipital alpha activity at 6 hours compared with baseline.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseLeft occipital alpha power at 6 hours
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    30 ml · oralAs given in this study (human).

    Measurements

    Baseline alpha power
    45.8%
    baseline
    Alpha power
    63.4%
    6 hours
    Baseline alpha power uncertainty (unspecified +/-)
    9.5%
    baseline alpha power 45.8%
    Alpha power uncertainty (unspecified +/-)
    9.8%
    6 hour alpha power after Cerebrolysin treatment
    Alpha power comparison p value
    < 0.05 p value
    left occipital electrode O1, 6 hour after Cerebrolysin versus baseline

    Source sentences

    Summary
    As compared with baseline alpha power (45.8+/-9.5%), the increase in relative alpha activity in the left occipital electrode (O1) reached significant values at 1 hour (57.2+/-8.5%; p < 0.05), 3 hours (59.4+/-7.6%; p < 0.05) and 6 hours (63.4+/-9.8%; p < 0.05) after Cerebrolysin administration.
    1 context sentence
    Summary · context
    The effects of a single oral dose of the Cerebrolysin solution (30 ml) on brain bioelectrical activity and on cognitive performance were investigated in healthy elderly people.
  5. 05HumanNon-randomized trialEfficacy outcome

    In healthy elderly people, Cerebrolysin decreased slow delta activity, with the maximum decrease at 6 hours.

    In plain wordsIn healthy elderly people, Cerebrolysin decreased slow brain delta activity compared with baseline.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseSlow delta activity
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Receptor activity and mechanism · Nervous system and cognition
    Studied dose
    30 ml · oralAs given in this study (human).

    Source sentences

    Summary
    Enhancement in relative alpha power was accompanied by a generalized decrease in slow delta activity that was maximum at 6 hours after Cerebrolysin intake.
    1 context sentence
    Summary · context
    The effects of a single oral dose of the Cerebrolysin solution (30 ml) on brain bioelectrical activity and on cognitive performance were investigated in healthy elderly people.
  6. 06HumanNon-randomized trialEfficacy outcome

    In healthy elderly people, Cerebrolysin reduced memory errors compared with baseline.

    In plain wordsIn healthy elderly people, Cerebrolysin reduced memory errors compared with baseline.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseADAS cog memory errors
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    30 ml · oralAs given in this study (human).

    Measurements

    Memory errors
    6.9 errors
    baseline
    Memory errors
    4.9 errors
    after treatment
    Memory errors uncertainty (unspecified +/-)
    1 errors
    baseline
    Memory errors uncertainty (unspecified +/-)
    1 errors
    after Cerebrolysin treatment
    Memory errors comparison p value
    < 0.01 p value
    after Cerebrolysin treatment versus baseline

    Source sentences

    Summary
    A significant improvement in memory performance, evaluated with items of the ADAS cog, was also found in elderly people taken a single dose of oral Cerebrolysin (6.9+/-1.0 errors at baseline versus 4.9+/-1.0 errors after treatment; p < 0.01).
    1 context sentence
    Summary · context
    The effects of a single oral dose of the Cerebrolysin solution (30 ml) on brain bioelectrical activity and on cognitive performance were investigated in healthy elderly people.
  7. 07HumanNon-randomized trialEfficacy outcome

    In healthy elderly people, Cerebrolysin reduced recognition errors compared with baseline.

    In plain wordsIn healthy elderly people, Cerebrolysin reduced recognition errors compared with baseline.

    Peptide
    Cerebrolysin
    Outcome
    DecreaseRecognition errors
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    30 ml · oralAs given in this study (human).

    Measurements

    Recognition errors
    2.8 errors
    baseline
    Recognition errors
    1.5 errors
    after treatment
    Recognition errors uncertainty (unspecified +/-)
    0.6 errors
    baseline
    Recognition errors uncertainty (unspecified +/-)
    0.7 errors
    after Cerebrolysin treatment
    Recognition errors comparison p value
    < 0.05 p value
    after Cerebrolysin treatment versus baseline

    Source sentences

    Summary
    This memory improvement was more evident in recognition (2.8+/-0.6 errors vs. 1.5+/-0.7 errors; p < 0.05) than in recall tasks (4.1+/-0.5 errors versus 3.4+/-0.5 errors; ns).
    1 context sentence
    Summary · context
    The effects of a single oral dose of the Cerebrolysin solution (30 ml) on brain bioelectrical activity and on cognitive performance were investigated in healthy elderly people.
  8. 08HumanNon-randomized trialEfficacy outcome

    In healthy elderly people, Cerebrolysin did not significantly reduce recall errors compared with baseline.

    In plain wordsIn healthy elderly people, Cerebrolysin did not significantly reduce recall errors compared with baseline.

    Peptide
    Cerebrolysin
    Outcome
    No significant changeRecall errors
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Cognition and memory · Nervous system and cognition
    Studied dose
    30 ml · oralAs given in this study (human).

    Measurements

    Recall errors
    4.1 errors
    baseline
    Recall errors
    3.4 errors
    after treatment
    Recall errors uncertainty (unspecified +/-)
    0.5 errors
    baseline
    Recall errors uncertainty (unspecified +/-)
    0.5 errors
    after Cerebrolysin treatment

    Source sentences

    Summary
    This memory improvement was more evident in recognition (2.8+/-0.6 errors vs. 1.5+/-0.7 errors; p < 0.05) than in recall tasks (4.1+/-0.5 errors versus 3.4+/-0.5 errors; ns).
    1 context sentence
    Summary · context
    The effects of a single oral dose of the Cerebrolysin solution (30 ml) on brain bioelectrical activity and on cognitive performance were investigated in healthy elderly people.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.